This document is provided for educational purposes only. It summarizes peer‑reviewed studies carried out in laboratory cells and animal models. The compounds discussed here—including FOXO4‑DRI and ES2—are experimental research tools and are not approved medicines. Nothing in this document should be considered a recommendation for use, purchase, or medical treatment. Always seek the guidance of qualified medical professionals for medical advice.
Our bodies contain cells that, after experiencing stress or damage, stop dividing. These cells are called senescent cells. While this process can protect us against cancer by stopping damaged cells from multiplying, it also has a downside. Senescent cells can linger in tissues and release a mix of signals that promote inflammation and disrupt normal tissue health. Because of this, researchers have been studying ‘senolytics’—agents designed to selectively remove senescent cells—as a way to better understand aging and age‑related diseases.
FOXO4‑DRI is a peptide that was designed to interfere with the interaction between two important proteins: FOXO4‑DRI and p53. Normally, FOXO4 helps keep senescent cells alive by binding to p53. When FOXO4‑DRI disrupts this interaction, p53 is free to trigger apoptosis, or programmed cell death, in the senescent cells. In experiments with mice, selectively removing senescent cells in this way restored tissue function and improved health markers in older animals (Baar et al., 2017). Additional research on cartilage cells suggested FOXO4‑DRI may have specific effects on senescent chondrocytes in the lab (Huang et al., 2021).
Researchers have also developed ES2, a newer peptide designed with the same goal of targeting the FOXO4–p53 pathway. Preclinical studies suggest that ES2 is between three to seven times more potent than FOXO4‑DRI in removing senescent cells, while showing fewer effects on normal cells. This means it may represent an improvement over the original FOXO4‑DRI design, at least in laboratory models (Tripathi et al., 2021; L’Hôte & Croisin, 2022; Czajkowski, 2024).
Beyond senolytics like FOXO4‑DRI and ES2, other peptides are sometimes mentioned in discussions about longevity. These are not senolytics, but they have been studied in other contexts:
• Epitalon (Ala‑Glu‑Asp‑Gly): Some studies in rodents and cell cultures suggest possible roles in telomere biology, but the evidence is inconsistent. In one well‑controlled study, Epitalon showed no effect on lifespan in mice (Anisimov, 2003).
• GHK‑Cu: This small copper‑binding peptide has been studied mostly for its roles in skin and wound healing. In laboratory models, it appears to influence DNA repair and tissue remodeling (Pickart, 2014; Pickart, 2018).
It is important to stress that none of these peptides—whether FOXO4‑DRI, ES2, Epitalon, or GHK‑Cu—are approved therapies. Human clinical trials are either very limited or entirely absent, and there is no evidence yet of clinical safety or effectiveness.
FOXO4‑DRI provided researchers with the first proof‑of‑concept that it may be possible to selectively clear senescent cells. ES2 builds upon this work with improved potency in preclinical studies. Other peptides like Epitalon and GHK‑Cu are often mentioned in the context of aging research, but they are not senolytics. The key point is that while laboratory findings are intriguing, translation into human health benefits remains an open question requiring rigorous clinical testing.
Q: Is FOXO4‑DRI a medicine?
A: No. FOXO4‑DRI is an experimental peptide that has only been studied in cells and animals. It is not an approved drug.
Q: Does ES2 work better than FOXO4‑DRI in people?
A: There are currently no human studies. In laboratory and animal models, ES2 appears more potent than FOXO4‑DRI, but whether this translates to people is unknown.
Q: Are Epitalon or GHK‑Cu senolytics?
A: No. Epitalon and GHK‑Cu have been studied in aging and tissue models, but they do not selectively clear senescent cells.
Baar, M. P., et al. (2017). Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell. https://biomed-phd.i-med.ac.at/wp-content/uploads/2023/02/Baar-et-al.pdf
Le, O., et al. (2021). Structural basis of FOXO4 interactions and FOXO4‑DRI senolytic peptide mechanism. Computational and Structural Biotechnology Journal. https://pmc.ncbi.nlm.nih.gov/articles/PMC8546421/
Huang, et al. (2021). FOXO4‑DRI selectively targets senescent chondrocytes. Frontiers in Bioengineering and Biotechnology. https://www.frontiersin.org/articles/10.3389/fbioe.2021.677576/full
Tripathi, U., et al. (2021). A next‑generation senolytic peptide with enhanced activity. EBioMedicine. https://pmc.ncbi.nlm.nih.gov/articles/PMC8601985/
L’Hôte, D., & Croisin, T. (2022). Senolytics and peptide therapeutics: review of mechanisms and prospects. Royal Society Open Biology. https://royalsocietypublishing.org/doi/10.1098/rsob.220171
Czajkowski, K. (2024). Advances in senescence‑targeting therapeutics. Frontiers in Aging. https://pmc.ncbi.nlm.nih.gov/articles/PMC11996976/
Anisimov, V. N., et al. (2003). Effect of Epitalon on lifespan in mice. Gerontology. https://pubmed.ncbi.nlm.nih.gov/14501183/
Pickart, L. (2014). GHK‑Cu in skin regeneration and wound healing. International Journal of Cosmetic Science. https://pmc.ncbi.nlm.nih.gov/articles/PMC4180391/
Pickart, L. (2018). The human tri‑peptide GHK‑Cu and its effects on gene expression. BioMed Research International. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
